Search Results - "Wilkins, A. Katharina"

The Per2 negative feedback loop sets the period in the mammalian circadian clock mechanism by Wilkins, A Katharina, Barton, Paul I, Tidor, Bruce

“…Processes that repeat in time, such as the cell cycle, the circadian rhythm, and seasonal variations, are prevalent in biology. Mathematical models can…”
Get full text

ABCL-367 Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL by Li, Yuezhe, Wilkins, A. Katharina, Knab, Timothy, Keir, Chris, Boni, Joseph P.

“…Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is an antibody–drug conjugate comprising an anti-CD19 antibody conjugated to a…”
Get full text

Quantitative Systems Pharmacology Modeling of Loncastuximab Tesirine Combined With Mosunetuzumab and Glofitamab Helps Guide Dosing for Patients With DLBCL by Li, Yuezhe, Katharina Wilkins, A., Knab, Timothy, Keir, Chris, Boni, Joseph P.

Get full text

ABCL-366 Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma by Li, Yuezhe, Wilkins, A. Katharina, Davis, Jimena, Knab, Timothy, Keir, Chris, Boni, Joseph P.

“…Loncastuximab tesirine (loncastuximab tesirine-lpyl [Lonca]) is an antibody–drug conjugate comprising an anti-CD19 antibody conjugated to a…”
Get full text

Quantitative Systems Pharmacology Model Predicts Combination Activity of CD19-Targeted Loncastuximab Tesirine Co-Dosed With a CD20/CD3 T-Cell Bispecific (Epcoritamab) in Diffuse Large B-Cell Lymphoma by Li, Yuezhe, Katharina Wilkins, A., Davis, Jimena, Knab, Timothy, Keir, Chris, Boni, Joseph P.

Get full text

Abstract 875: Quantitative systems pharmacology modeling of loncastuximab tesirine combined with mosunetuzumab and glofitamab helps guide dosing for patients with DLBCL by Li, Yuezhe, Wilkins, A Katharina, Knab, Tim, Boni, Joseph P.

“…Abstract Introduction: CD19 and CD20, B-lymphocyte surface antigens, are clinically validated therapeutic targets for the treatment of B-cell malignancies…”
Get full text

Abstract 1919: Prediction of systemic cytokine exposure in human after IV administration of oncolytic myxoma virus, using quantitative systems pharmacology modeling by Wilkins, A. Katharina, Franco, Lina S., Marcantonio, Diana H., Sutton, Karyn L., Apgar, Joshua F., Burke, John M., McFadden, Grant, Hua, Fei, Sharp, Leslie L.

“…Abstract A quantitative systems pharmacology (QSP) model of oncolytic immunotherapies based on the myxoma virus (MYXV) platform was constructed to project…”
Get full text

Abstract 4266: Computational exploration of mechanistic determinants of ADC pharmacokinetics using QSP modeling strategies by Wilkins, A. Katharina, Matteson, Andrew, Gruenbaum, Lore, Park, Jennifer, Burke, John M., Apgar, Joshua F.

“…Abstract The pharmacokinetics of antibody drug conjugate (ADC) therapeutics typically show a discrepancy between the PK of total antibody (conjugated and…”
Get full text

Abstract 4061: Computational exploration of mechanistic determinants of antibody drug-conjugate pharmacokinetics using quantitative systems pharmacology modeling strategies by Wilkins, A. Katharina, Matteson, Andrew, Gruenbaum, Lore, Park, Jennifer, Burke, John M., Apgar, Joshua

“…Abstract The pharmacokinetics of antibody drug conjugate (ADC) therapeutics typically show a discrepancy between the PK of total antibody (conjugated and…”
Get full text